Case Report

Anaerobic Spondylodiscitis due to *Fusobacterium* Species: A Case Report Review of the Literature

Tiffany N. Latta,¹ Aimee L. Mandapat,²,³ and Joseph P. Myers²,³

¹Department of Medicine, Summa Akron City Hospital, Akron, OH 44304, USA
²Division of Infectious Diseases, Department of Medicine, Summa Akron City Hospital, Akron, OH 44304, USA
³Section of Infectious Diseases, Department of Internal Medicine, Northeast Ohio Medical University, Rootstown, OH 44272, USA

Correspondence should be addressed to Joseph P. Myers; joseph.myers@summahealth.org

Received 11 February 2015; Accepted 16 April 2015

Academic Editor: Alexandre R. Marra

Copyright © 2015 Tiffany N. Latta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Spondylodiscitis caused by *Fusobacterium* species is rare. Most cases of spontaneous spondylodiscitis are caused by *Staphylococcus aureus* and most postoperative cases are caused by *Staphylococcus aureus* or coagulase-negative staphylococci. *Escherichia coli* is the most common Gram-negative organism causing spondylodiscitis. *Fusobacterium* species are unusual causes for anaerobic spondylodiscitis. We report the case of a patient with spontaneous L2-L3 spondylodiscitis, vertebral osteomyelitis, and epidural abscess caused by *Fusobacterium* species and review the literature for patients with *Fusobacterium* spondylodiscitis.

1. Introduction

Spondylodiscitis due to *Fusobacterium* species is unusual with only 15 cases having been previously reported [1–13]. Hematogenous spondylodiscitis is most often caused by *Staphylococcus aureus* [14–16]. Postoperative spondylodiscitis is most commonly due to staphylococcal species [17]. The most common etiologic agent of spontaneous Gram-negative spondylodiscitis is *Escherichia coli* [18]. *Propionibacterium* and *Bacteroides* species are the most commonly reported causes for anaerobic spondylodiscitis [19]. We report a patient with spontaneous L2-L3 spondylodiscitis due to *Fusobacterium* species and review the literature for other reports of this disease.

2. Materials and Methods

PubMed and Google Scholar searches were performed using the words discitis, diskitis, spondylodiscitis, vertebral osteomyelitis, and *Fusobacterium* looking for previously reported cases of discitis and osteomyelitis caused by *Fusobacterium* species. References from each of the articles obtained by these searches were also reviewed for further pertinent case reports.

3. Case Report

A 57-year-old man with a past history of asthma was admitted to the hospital with a three-month history of gradually worsening low back pain aggravated by movement and not improved with rest, cyclobenzaprine, or a tapering course of prednisone. Physical examination revealed multiple abscessed teeth and tenderness to palpation over the second and third lumbar vertebrae. The neurologic examination was normal. Complete blood count revealed a WBC of 13,600/cmm (normal: 4.400–11,300/cmm) with 93.4% granulocytes, 5.6% lymphocytes, and 1.0% monocytes. Erythrocyte sedimentation rate was 6 mm/hr (normal: 0–10 mm/hr). C-reactive protein was 3.68 mg/dL (normal: <0.6 mg/dL). MRI of the lumbar spine revealed severe L2-L3 discitis, contiguous L2 and L3 vertebral osteomyelitis with end-plate erosion, and epidural and psoas muscle abscesses. CT-guided biopsy was performed and a pure culture of *Fusobacterium* species was isolated from anaerobic cultures of the disc-space tissue aspirate. Fungal and mycobacterial cultures were negative. The abscessed teeth were extracted and the patient was successfully treated with ertapenem, one gram intravenously daily for 8 weeks. Follow-up examination 6 months later showed mild residual pain and a normal physical examination.
| Author [reference] | Year | Age (years) | Sex | Spinal level(s) | Underlying conditions | Microbiologic diagnosis | Antimicrobial therapy | Length of antimicrobial therapy | Surgical intervention | Outcome |
|-------------------|------|-------------|-----|----------------|-----------------------|------------------------|-----------------------|--------------------------|----------------------|---------|
| Fain et al. [4]   | 1989 | 67          | F   | L1-L2          | Cirrhosis; dental abscesses | Blood cultures: *F. nucleatum* | Amoxicillin-clavulanate PO + metronidazole PO × 6 weeks | 6 weeks | None | Lived |
| Rubin et al. [11] | 1991 | 58          | M   | T12-L1         | Diabetes mellitus, periodontitis | Disc biopsy (puncture): *Fusobacterium* sp. + *S. aureus* + *S. sanguis* type II | Clindamycin (route of administration not specified) × 8 weeks | 8 weeks | Dental extractions | Lived |
| Soubrier et al. [12] | 1995 | 63          | M   | T10-T11        | None | Blood cultures: *F. nucleatum* | Penicillin G IV + metronidazole IV × 3 days and then penicillin V PO × 2 months | 8 weeks | None | Lived |
| Wang et al. [13]  | 1996 | 48          | M   | L1-L2          | Periodontitis | Blood cultures: *F. nucleatum* | Penicillin G IV × 28 days and then clindamycin PO × 8 weeks | 12 weeks | Dental extractions | Lived well 20 months later |
| Pampliega-Martinez et al. [9] | 1997 | 84          | M   | T6-T7          | Thoracic contusion | Disc aspirate: *F. necrophorum* | Amoxicillin PO × 46 days | 8 weeks | None | Lived well 3 years later |
| de Gans et al. [3] | 2000 | 53          | F   | L4-L5          | Otitis media 5 months previously | Disc aspirate: *F. varium* | Amoxicillin-clavulanate PO × 8 weeks | 8 weeks | Drainage of epidural abscess via anterior approach with anterior spinal stabilization | Lived well 6 months later |
| Abele-Horn et al. [1] | 2001 | 20          | M   | L4-L5          | *Mycoplasma pneumonia* pneumonia 3 weeks previously | Blood cultures: *F. necrophorum* | Ampicillin/sulbactam IV × 3 days and then imipenem-cilastatin IV × 4 weeks and then clindamycin PO × 3 months | 19 weeks | None | Lived well 1 year later |
| Brook [2]         | 2001 | 8           | M   | L3-L4          | Upper respiratory infection 27 days previously | Disc aspirate: *F. nucleatum* | Clindamycin IV × 3 weeks and then clindamycin PO × 3 weeks | 6 weeks | None | Lived well 2 years later |
| Le Moal et al. [8]  | 2005 | 78          | F   | L5-S1          | Periodontitis requiring right inferior molar extraction 3 months previously | Disc aspirate and blood cultures: *F. necrophorum* | Clindamycin IV × 4 weeks and then clindamycin PO × 8 wks. | 12 weeks | None | Lived well 2 years later |
| Author [reference] | Year | Age (years) | Sex | Spinal level(s) | Underlying conditions | Microbiologic diagnosis | Antimicrobial therapy | Length of antimicrobial therapy | Surgical intervention | Outcome                  |
|-------------------|------|-------------|-----|----------------|-----------------------|------------------------|-----------------------|--------------------------|---------------------|-------------------------|
| Le Moal et al. [8] | 2005 | 62          | M   | L4-L5          | None                  | Blood cultures: F. necrophorum | Clindamycin IV × 4 weeks and then clindamycin PO × 8 weeks | 12 weeks                | None                | Lived well 2 years later |
| Le Moal et al. [8] | 2005 | 61          | M   | T6–T8          | Diabetes mellitus; periodontal disease | Bone aspirate and blood cultures: F. nucleatum | Penicillin G IV × 4 weeks and then clindamycin PO × 8 weeks | 12 weeks                | Dental extractions    | Lived well 3 years later |
| Goolamali et al. [5] | 2006 | 63          | M   | L4-L5          | Dental root abscess | Disc aspirate and open biopsy: F. nucleatum | Flucloxacillin IV + fusidic acid IV and then penicillin G IV + metronidazole (unknown route of administration) | Unknown | Right L5 laminectomy + drainage of multilevel epidural abscess | Lived well 2 months later |
| Joosten et al. [7]  | 2011 | 70          | M   | L3-L4          | None                  | Blood cultures: F. nucleatum | Amoxicillin-clavulanate IV × 1 day, then ceftriaxone IV + metronidazole PO × 3 days, then metronidazole PO × 3.5 weeks, and then clindamycin PO × 14.5 weeks | 19 weeks                | None                | Lived well 6 wks. after treatment |
| Ramos et al. [10]  | 2013 | 42          | F   | L3-L4          | Crohn's disease      | Disc aspirate: F. nucleatum | Ertapenem IV + metronidazole PO × 8 weeks and then amoxicillin-clavulanate PO × 10 weeks | 18 weeks                | None                | Lived well 7 months later |
| Griffin and Christensen [6] | 2014 | 38          | M   | L3-L4          | Gingivitis; contusions after all-terrain vehicle rollover | Open biopsy: F. nucleatum | Ertapenem IV × 8 weeks and then amoxicillin PO indefinitely | Indefinite suppressive therapy | Debridement and spinal fusion of L2–L5 | Unknown |
| Latta et al. [this case] | 2015 | 57          | M   | L2-L3          | Asthma               | Disc aspirate: Fusobacterium species | Ertapenem IV × 8 weeks | 8 weeks               | None                | Lived well 3 months after treatment |
4. Discussion

*Fusobacterium* is a genus of obligately anaerobic filamentous Gram-negative rods that are members of the phylum Fusobacteria [20, 21]. They can be divided into 13 species that inhabit the oral, gastrointestinal, upper respiratory tract, and vaginal mucosa [22]. *Fusobacterium* species can be variable in Gram stain morphology and display a range of cellular morphologies from coccoid, pleomorphic spherules to rod shaped organisms. Rods can be short with rounded ends or long with pointed ends. Most *Fusobacterium* species are indole positive and produce butyric acid during the fermentation of glucose [20, 21]. *Fusobacterium nucleatum* is the species most commonly described causing human infection and Lemierre’s syndrome caused by *Fusobacterium necrophorum* is the best known infection associated with the Fusobacteria [23, 24]. Fusobacterial infections of almost every anatomic site have been reported [23, 24]. Bacteremia caused by *Fusobacterium* species is unusual but not rare [25–27]. Several patients with fusobacterial vertebral and paravertebral infections without classic spondylodiscitis have also been reported [28–31].

Patients with fusobacterial spondylodiscitis reported in the literature are listed in Table I. Patient ages ranged from 8 to 84 years with a mean of 54.5 years. There were 12 men (75%) and 4 women (25%). The most common spinal level for spondylodiscitis was the lumber area. There were 4 patients with thoracic disease (25%) and 12 with lumbar disease (75%). L3–L4 and L4–L5 discitis were most common with 4 patients with disease at each of those sites. One patient had multilevel disease (T6–T8). Three patients had no underlying illness. Seven of 16 patients (43.75%) had significant oral pathology: one had insertion of a central venous catheter [20, 21]. The duration of antimicrobial therapy was curative in all reported patients, although three patients required surgical intervention for complications such as paraspinal phleghmon. *Fusobacterium* isolates are usually sensitive to penicillin, ampicillin, amoxicillin/clavulanate, piperacillin/tazobactam, clindamycin, metronidazole, moxifloxacin, tigecycline, imipenem, and ertapenem [20, 21]. Because *Fusobacterium* spp. are often part of polymicrobial infectious flora, therapy should be guided by both available sensitivity testing and the potential presence of other aerobic/anaerobic organisms in cultures from the site of infection. Because of its once daily administration schedule and its antimicrobial spectrum, ertapenem is an especially attractive treatment option when outpatient parenteral antimicrobial therapy (OPAT) is being used. Moxifloxacin, a fluoroquinolone with high oral bioavailability, once daily administration, and aerobic/anaerobic spectrum, is an attractive oral alternative to OPAT with its requisite peripherally inserted central venous catheter [20, 21].

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this article.

References

[1] M. Abele-Horn, P. Emmerling, and J. F. E. Mann, “Lemierre’s syndrome with spondylitis and pulmonary and gluteal abscesses associated with *Mycoplasma pneumoniae pneumonia,*” European Journal of Clinical Microbiology and Infectious Diseases, vol. 20, no. 4, pp. 263–266, 2001.

[2] I. Brook, “Two cases of diskitis attributable to anaerobic bacteria in children,” Pediatrics, vol. 107, no. 2, article e26, 2001.

[3] J. de Gans, S. Schade van Westrum, E. Kuipper, and G. R. Schap, “Earache and back pain,” The Lancet, vol. 355, no. 9202, p. 464, 2000.

[4] O. Fain, T. Bardin, I. Cheour, F. Legmann, A. Felten, and D. Kuntz, “Spondylodiscitis caused by *Fusobacterium nucleatum*,” Apropos de 1 cas,” Revue du Rhumatisme et des Maladies Ostéo- Articulaires, vol. 56, no. 4, pp. 339–340, 1989.

[5] S. I. Goolamali, M. T. Carulli, and U. M. Davies, “Spinal abscess and mitral valve endocarditis secondary to asymptomatic fusobacterium-induced dental abscess,” Journal of the Royal Society of Medicine, vol. 99, no. 7, pp. 368–369, 2006.

[6] A. T. Griffin and D. Christensen, “Fusobacterium spondylodiscitis: case report and literature review,” Diagnostic Microbiology and Infectious Disease, vol. 78, no. 4, pp. 491–493, 2014.

[7] A. Joosten, J. Verhaegen, and E. Van Wijngaerden, “Fusobacterium nucleatum spondylodiscitis: case report and literature review,” Clinical Microbiology Newsletter, vol. 33, no. 15, pp. 115–117, 2011.

[8] G. Le Moal, L. Juhel, G. Grollier, C. Godet, I. Azaiz, and A. Roblot, “Vertebral osteomyelitis due to *Fusobacterium* species: report of three cases and review of the literature,” Journal of Infection, vol. 51, no. 2, pp. E5–E9, 2005.

[9] T. Pampilea-Martinez and A. Arenas-Planelles, “Espontodiscitis por *Fusobacterium necrophorum*: a propósito de un caso,” Revista Española de Cirugía Osteoarticular, vol. 32, no. 192, pp. 284–288, 1997.

[10] A. Ramos, E. Berbari, and P. Huddleston, “Diagnosis and treatment of fusobacterium nucleatum discitis and vertebral...
osteoarthrosis: case report and review of the literature,” *Spine*, vol. 38, no. 2, pp. E120–E122, 2013.

[11] M. M. Rubin, R. J. Sanfilippo, and R. S. Sadoff, “Vertebral osteomyelitis secondary to an oral infection,” *Journal of Oral and Maxillofacial Surgery*, vol. 49, no. 8, pp. 897–900, 1991.

[12] M. Soubrier, Z. Urosevic, J. J. Dubost, J. M. Ristori, and J. L. Bussière, “Spondylodiscitis caused by *Fusobacterium nucleatum*. Apropos of a case,” *Presse Médecin*, vol. 24, no. 21, pp. 989–991, 1995.

[13] T.-D. Wang, Y.-C. Chen, and P.-J. Huang, “Recent recurrent vertebral osteomyelitis and psoas abscess caused by *Streptococcus constellatus* and *Fusobacterium nucleatum* in a patient with atrial septal defect and an occult dental infection,” *Scandinavian Journal of Infectious Diseases*, vol. 28, no. 3, pp. 309–310, 1996.

[14] L. Cottle and T. Riordan, “Infectious spondylodiscitis,” *Journal of Infectious Diseases*, vol. 56, no. 6, pp. 401–412, 2008.

[15] T. Gouliouris, S. H. Aliyu, and N. M. Brown, “Spondylodiscitis: update on diagnosis and management,” *Journal of Antimicrobial Chemotherapy*, vol. 65, supplement 3, pp. iii11–iii24, 2010.

[16] J. M. Nolla, J. Ariza, C. Gómez-Vaquero et al., “Spontaneous pyogenic vertebral osteomyelitis in nondrug users,” *Seminars in Arthritis and Rheumatism*, vol. 31, no. 4, pp. 271–278, 2002.

[17] M. E. Jimenez-Mejias, J. de Dios Colmenero, F. J. Sánchez-Lora et al., “Postoperative spondylodiskitis: etiology, clinical findings, prognosis, and comparison with nonoperative pyogenic spondylodiskitis,” *Clinical Infectious Diseases*, vol. 29, no. 2, pp. 339–345, 1999.

[18] K.-H. Park, O. H. Cho, M. Jung et al., “Infectious spondylodiscitis: case series and systematic review,” *Southern Medical Journal*, vol. 98, no. 2, pp. 144–148, 2005.

[19] W. S. Garrett and A. B. Onderdonk, “*Bacteroides*, *Prevotella*, Porphyromonas, and *Fusobacterium* species (and other medically important anaerobic Gram-negative bacilli),” in *Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases*, J. E. Bennett, R. Dolin, and M. J. Blaser, Eds., pp. 2773–2780, WB Saunders, Philadelphia, Pa, USA, 2015.

[20] E. Kononen, W. G. Wade, and D. M. Citron, “*Bacteroides*, *Porphyromonas*, *Prevotella*, *Fusobacterium*, and other anaerobic gram-negative rods,” in *Manual of Clinical Microbiology*, J. Versalovic, Ed., pp. 858–880, ASM Press, Washington, DC, USA, 10th edition, 2011.

[21] D. M. Citron, “Update on the taxonomy and clinical aspects of the genus *Fusobacterium*,” *Clinical Infectious Diseases*, vol. 35, no. 1, pp. S22–S27, 2002.

[22] D. M. Citron, D. M. Huggan, and D. R. Murdoch, “Fusobacterial infections: clinical spectrum and incidence of invasive disease,” *Journal of Infection*, vol. 57, no. 4, pp. 283–289, 2008.

[23] E. Pett, K. Saeed, and M. Dryden, “*Fusobacterium* species infections: clinical spectrum and outcomes at a district general hospital.” *Infection*, vol. 42, no. 2, pp. 363–370, 2014.

[24] K. Afra, K. Laupland, J. Leal, T. Lloyd, and D. Gregson, “Incidence, risk factors, and outcomes of *Fusobacterium* species bacteremia,” *BMC Infectious Diseases*, vol. 13, article 264, 2013.

[25] A.-M. Bourgault, F. Lamothe, P. Dolcé, L. Saint-Jean, and P. Saint-Antoine, “*Fusobacterium* bacteremia: clinical experience with 40 cases,” *Clinical Infectious Diseases*, vol. 25, no. 2, pp. S181–S183, 1997.